Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0915 Deals QTs
BioCentury & Getty Images


Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology 

Sep 16, 2020 | 1:14 AM GMT

NIH launches Accelerating Medicines Partnership for schizophrenia
NIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative to find biomarkers that identify individuals at risk for developing schizophrenia, predict the likelihood

Read the full 663 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers